Neumora Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
IND application for NMRA-215 (NLRP3 inhibitor) submitted to the U.S. Food and Drug Administration
IND application for NMRA-215 (NLRP3 inhibitor) submitted to the U.S. Food and Drug Administration